Long-term outcomes of operable stage III NSCLC in the pre-immunotherapy era: results from a pooled analysis of the SAKK 16/96, SAKK 16/00, SAKK 16/01, and SAKK 16/08 trials.

Publication

Long-term outcomes of operable stage III NSCLC in the pre-immunotherapy era: results from a pooled analysis of the SAKK 16/96, SAKK 16/00, SAKK 16/01, and SAKK 16/08 trials.

Journal Paper/Review - Apr 7, 2022

König D P, Scharl Sylvie, Vuong D, Guckenberger M, Furrer Katarzyna, Opitz Isabella, Weder W, Rothschild S I, Ochsenbein A, Zippelius A, Addeo Alfredo, Mark M, Eboulet E I, Hayoz S, Thierstein S, Betticher D C, Ris H-B, Stupp R, Curioni-Fontecedro A, Peters S, Pless M, Früh M

Citation

König D, Scharl S, Vuong D, Guckenberger M, Furrer K, Opitz I, Weder W, Rothschild S, Ochsenbein A, Zippelius A, Addeo A, Mark M, Eboulet E, Hayoz S, Thierstein S, Betticher D, Ris H, Stupp R, Curioni-Fontecedro A, Peters S, Pless M, Früh M. Long-term outcomes of operable stage III NSCLC in the pre-immunotherapy era: results from a pooled analysis of the SAKK 16/96, SAKK 16/00, SAKK 16/01, and SAKK 16/08 trials. ESMO Open 2022; 7:100455.

Type

Journal Paper/Review (English)

Journal

ESMO Open 2022; 7

Publication Date

Apr 7, 2022

Issn Electronic

2059-7029

Pages

100455

Brief description/objective

Chemoradiotherapy with durvalumab consolidation has yielded excellent results in stage III non-small-cell lung cancer (NSCLC). Therefore, it is essential to identify patients who might benefit from a surgical approach.